Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
Abstract The US Food and Drug Administration approves tissue-agnostic therapies to target tumor biomarkers regardless of tumor type. In light of the growing number of such approvals in recent years, a better understanding of their relative clinical benefit across cancer types is required. To address...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Nature Portfolio
2025-03-01
|
| سلاسل: | Nature Communications |
| الوصول للمادة أونلاين: | https://doi.org/10.1038/s41467-025-57941-0 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|